Clinical Trials Browser

Active not recruiting × Triple Negative Breast Neoplasms × Gemcitabine × Clear all

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Phase 3 Active not recruiting

418 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Phase 1 Active not recruiting

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05181462 2026-04-06

TRIFOUR

Phase 1/2 Active not recruiting

117 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

350 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05347134 2025-12-09

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

254 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

443 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

87 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ToPCourT

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

TRIFOUR

ASCENT-03

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

ASCENT-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature